HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Gestational trophoblastic neoplasia — Clinical Guidelines

Overview

Gestational trophoblastic neoplasia (GTN) encompasses a spectrum of malignant conditions arising from trophoblastic cells, including choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor. These conditions often originate from molar pregnancies and can present with local invasion or distant metastasis. 1 5 7

Diagnosis

Incidental Diagnosis: Often diagnosed incidentally due to silent presentation.

Fetomaternal Hemorrhage (FMH): Linked to intraplacental choriocarcinoma and associated complications like stillbirth and intrauterine growth restriction. 1

Histological Confirmation: Post-delivery diagnosis common in intraplacental cases.

Serum hCG Levels: Monitoring serum human chorionic gonadotropin (hCG) levels crucial for diagnosis and treatment monitoring. 6

FIGO Scoring System: Utilizes risk factors and staging to categorize patients into low-risk or high-risk groups. 7 8

Management

First-Line Chemotherapy:

- High-Risk GTN (FIGO Score ≥5): Floxuridine, Actinomycin D, Etoposide, and Vincristine (FAEV) regimen shows efficacy with 85.3% complete remission rate. 3 - Standard Regimens: 5-fluorouracil-based multiagent chemotherapy remains common in many settings.

Adjunctive Treatments:

- Metastatic Disease: Multidisciplinary approach including surgery, radiation, and further chemotherapy as needed. - Toxicity Management: Close monitoring for neutropenia, thrombocytopenia, and anemia, especially with FAEV regimen. 3

Special Populations

Pregnancy: Twin pregnancies with a normal fetus and coexisting GTN require careful management balancing maternal and fetal health. 9

Comorbidities: High-risk features like PSTT histology, high FIGO scores, and chemotherapy resistance correlate with poorer outcomes. 5

Key Recommendations

Utilize FIGO risk scoring system for accurate staging and guiding treatment intensity (Evidence: Strong 7 8).

Employ FAEV regimen as a first-line treatment for high-risk GTN (FIGO Score ≥5) with close monitoring for toxicity (Evidence: Moderate 3).

Regularly monitor serum hCG levels for diagnosis and treatment response in GTN management (Evidence: Moderate 6).

Consider multidisciplinary approaches for managing metastatic GTN, incorporating surgery and radiation when necessary (Evidence: Expert opinion 5).

Address ethical concerns related to equitable access to advanced diagnostic tools like NIPT, especially in resource-limited settings (Evidence: Weak 4).

References

1 Stabile G, Gentile RM, Carlucci S, Stampalija T, Biffi S, Oletto G et al.. Maternal and fetal outcomes of intraplacental choriocarcinoma complicated by fetomaternal hemorrhage: a systematic review. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2023. link 2 Hui P, Webster F, Baergen RN, Buza N, Cheung ANY, Kaur B et al.. Dataset for the Reporting of Gestational Trophoblastic Neoplasia: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2022. link 3 Li Y, Kong Y, Wan X, Feng F, Ren T, Zhao J et al.. Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ≥5. The oncologist 2021. link 4 Hui L, Teoh M, Piessens S, Walker SP. Early clinical experience of cell-free DNA-based aneuploidy screening: A survey of obstetric sonologists in Australia and New Zealand. The Australian & New Zealand journal of obstetrics & gynaecology 2015. link 5 Kingdon SJ, Coleman RE, Ellis L, Hancock BW. Deaths from gestational trophoblastic neoplasia: any lessons to be learned?. The Journal of reproductive medicine 2012. link 6 Suzuki N, Aoki D, Orikawa K, Suzuki A, Susumu N, Tamada Y et al.. 8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin. Placenta 2006. link 7 Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. The Journal of reproductive medicine 2002. link 8 Kohorn EI. Gestational trophoblastic neoplasia and evidence-based medicine. The Journal of reproductive medicine 2002. link 9 Soysal M, Kara S, Ekici E. Twin pregnancy with a fetus and a complete hydatidiform mole. Archives of gynecology and obstetrics 1996. link

Gestational trophoblastic neoplasia